278 related articles for article (PubMed ID: 23508839)
21. Identification and survival outcomes of a cohort of patients with cancer of unknown primary in Ontario, Canada.
Kim CS; Hannouf MB; Sarma S; Rodrigues GB; Rogan PK; Mahmud SM; Winquist E; Brackstone M; Zaric GS
Acta Oncol; 2015 Nov; 54(10):1781-7. PubMed ID: 25825957
[TBL] [Abstract][Full Text] [Related]
22. [Liver transplantation in neuroendocrine tumors prolongs symptom-free period, might also be a cure].
Olausson M; Friman S; Johanson V; Nilsson O; Wängberg B; Ahlman H
Lakartidningen; 1999 Sep; 96(36):3783-6. PubMed ID: 10500396
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic work-up and outcome of cervical metastases from an unknown primary.
Guntinas-Lichius O; Peter Klussmann J; Dinh S; Dinh M; Schmidt M; Semrau R; Mueller RP
Acta Otolaryngol; 2006 May; 126(5):536-44. PubMed ID: 16698706
[TBL] [Abstract][Full Text] [Related]
24. Gamma knife surgery for brain metastases: indications for and limitations of a local treatment protocol.
Serizawa T; Saeki N; Higuchi Y; Ono J; Iuchi T; Nagano O; Yamaura A
Acta Neurochir (Wien); 2005 Jul; 147(7):721-6; discussion 726. PubMed ID: 15891808
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic Approaches to Neuroendocrine Neoplasms of Unknown Primary Site.
Berner AM; Pipinikas C; Ryan A; Dibra H; Moghul I; Webster A; Luong TV; Thirlwell C
Neuroendocrinology; 2020; 110(7-8):563-573. PubMed ID: 31658461
[TBL] [Abstract][Full Text] [Related]
26. Prognostication in cancer of unknown primary (CUP): development of a prognostic algorithm in 311 cases and review of the literature.
Petrakis D; Pentheroudakis G; Voulgaris E; Pavlidis N
Cancer Treat Rev; 2013 Nov; 39(7):701-8. PubMed ID: 23566573
[TBL] [Abstract][Full Text] [Related]
27. Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer.
Riihimäki M; Thomsen H; Hemminki A; Sundquist K; Hemminki K
BMC Cancer; 2013 Jan; 13():36. PubMed ID: 23356713
[TBL] [Abstract][Full Text] [Related]
28. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
[TBL] [Abstract][Full Text] [Related]
29. Surgical treatment of neuroendocrine tumors of the lung.
Daddi N; Ferolla P; Urbani M; Semeraro A; Avenia N; Ribacchi R; Puma F; Daddi G
Eur J Cardiothorac Surg; 2004 Oct; 26(4):813-7. PubMed ID: 15450578
[TBL] [Abstract][Full Text] [Related]
30. Capsule endoscopy to detect primary tumour site in metastatic neuroendocrine tumours.
Frilling A; Smith G; Clift AK; Martin J
Dig Liver Dis; 2014 Nov; 46(11):1038-42. PubMed ID: 25086997
[TBL] [Abstract][Full Text] [Related]
31. [Treatment and prognosis of stage IV alveolar soft part sarcoma].
Zhao J; Yang Y
Zhonghua Zhong Liu Za Zhi; 2012 Dec; 34(12):932-6. PubMed ID: 23336381
[TBL] [Abstract][Full Text] [Related]
32. [Neuroendocrine tumors of the lung].
Oliaro A; Donati G; Filosso PL; Ruffini E
Minerva Chir; 2000; 55(1-2):7-16. PubMed ID: 10832278
[TBL] [Abstract][Full Text] [Related]
33. Surgery with complete resection improves survival in radiooncologically treated patients with cervical lymph node metastases from cancer of unknown primary.
Hauswald H; Lindel K; Rochet N; Debus J; Harms W
Strahlenther Onkol; 2008 Mar; 184(3):150-6. PubMed ID: 18330511
[TBL] [Abstract][Full Text] [Related]
34. Neuroendocrine Merkel cell nodal carcinoma of unknown primary site: management and outcomes of a rare entity.
Kotteas EA; Pavlidis N
Crit Rev Oncol Hematol; 2015 Apr; 94(1):116-21. PubMed ID: 25573607
[TBL] [Abstract][Full Text] [Related]
35. Cytoreductive surgery in advanced endocrine tumours of the pancreas.
Pederzoli P; Falconi M; Bonora A; Salvia R; Sartori N; Contro C; Marcucci S; Bassi C
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S207-12. PubMed ID: 10604132
[TBL] [Abstract][Full Text] [Related]
36. [Expert dialogue: neuroendocrine tumours of the lungs and gastroenteropancreatic system].
Hörsch D; Sayeg Y; Bonnet R; Kaemmerer D; Presselt N; Baum RP
Pneumologie; 2012 Jan; 66(1):44-8. PubMed ID: 22250054
[TBL] [Abstract][Full Text] [Related]
37. Identification of Areas for Improvement in the Management of Bone Metastases in Patients with Neuroendocrine Neoplasms.
Lim KHJ; Raja H; D'Arienzo P; Barriuso J; McNamara MG; Hubner RA; Mansoor W; Valle JW; Lamarca A
Neuroendocrinology; 2020; 110(7-8):688-696. PubMed ID: 31639796
[TBL] [Abstract][Full Text] [Related]
38. Well-differentiated neuroendocrine neoplasia: relapse-free survival and predictors of recurrence after curative intended resections.
Dieckhoff P; Runkel H; Daniel H; Wiese D; Koenig A; Fendrich V; Bartsch DK; Moll R; Müller D; Arnold R; Gress T; Rinke A
Digestion; 2014; 90(2):89-97. PubMed ID: 25196446
[TBL] [Abstract][Full Text] [Related]
39. [The clinical characteristic of 43 cases of neuroendocrine tumors with liver metastases].
Li P; Yang XO; Qian JM
Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):289-93. PubMed ID: 22781949
[TBL] [Abstract][Full Text] [Related]
40. [Lymph node metastasis removed, occult primary tumor. How to proceed?].
Füessl HS; Stiefelhagen P
MMW Fortschr Med; 2012 Nov; 154(20):32. PubMed ID: 23234116
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
